Welcome to the CCRA Website

We are an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer and improve survivor outcomes. Our members include federal research funding programs/agencies, provincial research agencies, provincial cancer care agencies, cancer charities, and other voluntary associations. 

We are motivated by the belief that, through effective collaboration, Canadian cancer research funding organizations can maximize their collective impact on cancer control and accelerate discovery for the ultimate benefit of Canadians affected by cancer.

Our Executive Office is supported by the Canadian Partnership Against Cancer, an independent, not-for-profit organization funded by the federal government to accelerate action on cancer control for all Canadians.

A New Executive Director for CCRA

CCRA welcomes Dr. Sara Urowitz as its new Executive Director. Sara has a PhD in Health Policy and Bioethics and was most recently the Group Manager, Palliative Care and the Ontario Palliative Care Network Secretariat at Cancer Care Ontario. Sara is also an Assistant Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. With a background in strategic planning, palliative care, and cancer survivorship, Sara is well placed to facilitate CCRA's work in these areas.

Dr. Stephen Robbins is the New CCRA Co-chair

At the recent CCRA Member Meeting, Dr. Stephen Robbins, Scientific Director, CIHR Institute of Cancer Research and Associate Professor, Departments of Oncology, Biochemistry & Molecular Biology, at the University of Calgary, became the incoming CCRA co-chair. Dr. Robbins was elected from among the organizational representatives and will serve a two-year term. Congratulations, Steve!

Members recognized the invaluable contributions of outgoing co-chair, Dr. Christine Williams, Chief Mission Officer and Scientific Director, Canadian Cancer Society, who served for three years. Dr. Williams played an instrumental role in the development of Target 2020, the delivery of the 2013 and 2015 research conferences, and the reports on cancer research investment. Thank you, Christine!

Cancer Research Investment in 2013

CCRA released the new cancer research investment figures for 2013. This brief report shows an annual investment of $498M for 2013, higher than the first four years of the survey, but the lowest amount since 2008. Much of the decline from 2009 to 2013 was attributable to reduced cancer-relevant investment from the Canada Foundation for Innovation and from provincial sources in Ontario. The investment in operating grants, however, continued its year-upon-year increase, with the ongoing trend of greater investment from “focused” funding programs compared to open operating grants. To access this report, detailed tables, and a companion slide deck, click here.

CCRC 2015 is a Resounding Success

The Canadian Cancer Research Conference (November 8-10, Montréal – Hôtel Bonaventure) continued its tradition of providing a scientific program that covers the full spectrum of cancer research with presentations by several of the country’s leading researchers. New to this year was a “Headline News” symposium, during which top researchers shared their recently released research findings. The conference was attended by 983 participants, about half of whom were trainees. For more information about the Conference, click here.

Other News and Events...

Latest edition of IARC WHO Classification of Tumours

Available February 2016, the WHO Classification of Tumors of the Urinary System and Male Genital Organs is the eighth volume in the 4th Edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. It contains numerous color photographs, MRIs, ultrasound images, CT scans, charts and references. For more information, see https://who.presswarehouse.com/books/BookDetail.aspx?productID=470635.